Literature DB >> 17540710

Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin.

Eniko Bodó1, Arno Kromminga, Wolfgang Funk, Magdalena Laugsch, Ute Duske, Wolfgang Jelkmann, Ralf Paus.   

Abstract

Erythropoietin primarily serves as an essential growth factor for erythrocyte precursor cells. However, there is increasing evidence that erythropoietin (EPO)/EPO receptor (EPO-R) signaling operates as a potential tissue-protective system outside the bone marrow. Arguing that growing hair follicles (HF) are among the most rapidly proliferating tissues, we have here explored whether human HFs are sources of EPO and targets of EPO-R-mediated signaling. Human scalp skin and microdissected HFs were assessed for EPO and EPO-R expression, and the effects of EPO on organ-cultured HFs were assessed in the presence/absence of a classical apoptosis-inducing chemotherapeutic agent. Here, we show that human scalp HFs express EPO on the mRNA and protein level in situ, up-regulate EPO transcription under hypoxic conditions, and express transcripts for EPO-R and the EPO-stimulatory transcriptional cofactor hypoxia-inducible factor-1alpha. Although EPO does not significantly alter human hair growth in vitro, it significantly down-regulates chemotherapy-induced intrafollicular apoptosis and changes the gene expression program of the HFs. The current study points to intriguing targets of EPO beyond the erythropoietic system: human HFs are an extrarenal site of EPO production and an extrahematopoietic site of EPO-R expression. They may recruit EPO/EPO-R signaling e.g., for modulating HF apoptosis under conditions of hypoxia and chemotherapy-induced stress.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540710     DOI: 10.1096/fj.07-8628com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

1.  Hormones and the pilosebaceous unit.

Authors:  Wen-Chieh Chen; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-03

Review 2.  Regulation of erythropoiesis by hypoxia-inducible factors.

Authors:  Volker H Haase
Journal:  Blood Rev       Date:  2013-01-03       Impact factor: 8.250

Review 3.  Hypoxic regulation of erythropoiesis and iron metabolism.

Authors:  Volker H Haase
Journal:  Am J Physiol Renal Physiol       Date:  2010-05-05

4.  Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera.

Authors:  Fabiana Perna; Nadia Gurvich; Ruben Hoya-Arias; Omar Abdel-Wahab; Ross L Levine; Takashi Asai; Francesca Voza; Silvia Menendez; Lan Wang; Fan Liu; Xinyang Zhao; Stephen D Nimer
Journal:  Blood       Date:  2010-06-28       Impact factor: 22.113

Review 5.  [The role of erythropoietin in improvement of wound healing].

Authors:  H Sorg; J W Kuhbier; B Menger; K Reimers; Y Harder; P M Vogt
Journal:  Chirurg       Date:  2010-11       Impact factor: 0.955

6.  Erythropoietin in sepsis: a new use for a familiar drug?

Authors:  Amy C Fox; Craig M Coopersmith
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

7.  Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Giuseppe Lippi
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

8.  Impaired synthesis of erythropoietin, glutamine synthetase and metallothionein in the skin of NOD/SCID/gamma(c)(null) and Foxn1 nu/nu mice with misbalanced production of MHC class II complex.

Authors:  L Danielyan; S Verleysdonk; M Buadze; C H Gleiter; G H Buniatian
Journal:  Neurochem Res       Date:  2009-10-14       Impact factor: 3.996

Review 9.  Anaemia in kidney disease: harnessing hypoxia responses for therapy.

Authors:  Mark J Koury; Volker H Haase
Journal:  Nat Rev Nephrol       Date:  2015-06-09       Impact factor: 28.314

10.  A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial.

Authors:  Christina Irene Günter; Augustinus Bader; Ulf Dornseifer; Silvia Egert; Sebastian Dunda; Gerrit Grieb; Thomas Wolter; Norbert Pallua; Tobias von Wild; Frank Siemers; Peter Mailänder; Oliver Thamm; Carsten Ernert; Michael Steen; Reiner Sievers; Bert Reichert; Afshin Rahmanian-Schwarz; Hans Schaller; Bernd Hartmann; Max Otte; Victoria Kehl; Christian Ohmann; Wolfgang Jelkmann; Hans-Günther Machens
Journal:  Trials       Date:  2013-05-03       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.